Regulation of Activity of Myeloid-Derived Suppressor Cells to Reduce Incidence of Staphylococcus auerus Induced Osteomyelitis

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that expands during cancer, inflammation and infection, and that has a remarkable ability to suppress T lymphocytes response. These cells constitute a unique component of the immune system that regulates immune responses in healthy individuals and in the context of various diseases. The first observations of suppressive myeloid cells were described more than 20 years ago in patients with cancer1.The functional importance of these cells in the immune system has recently been appreciated due to accumulating evidence that has demonstrated their contribution to the negative regulation of immune responses during cancer and other diseases. It is now becoming increasingly clear that this activity is contained within a population known as myeloid-derived suppressor cells (MDSCs). Features common to all MDSCs are their myeloid origin, immature state and a remarkable ability to suppress T lymphocytes response. In addition to their suppressive effects on adaptive immune responses, MDSCs have also been reported to regulate innate immune responses by modulating the cytokine production of macrophages2. However, as a discussion of these aspects of MDSCs biology in orthopedic disease; osteomyelitis, is still unclear3. In current study, we will analysis the activity and suppressive functions of MDSCs in treating Staphylococcus auerus induced osteomyelitis with biofilm formation, as well as the potential to target these cells for therapeutic benefit. Our preliminary data of animal study has showed Staphylococcus auerus induced biofilm could enhance suppress activity of MDSCs. Therefore, activated MDSCs could suppress T lymphocytes activity in osteomyelitis to reduce immunity in-vivo. We believe the incidence of chronic osteomyelitis could be diminished with regulation of MDSCs through antibiotic treatment, MDSCs inhibitor (COX2 inhibitor) and hyperbaric oxygen therapy (HBOT) in the future.

Project ID:PC10207-0315
External Project ID:NSC102-2314-B182A-118